Synagis (palivizumab) to prevent respiratory syncytial virus (RSV) infections in young children

November 1998

Physicians can now use Synagis (palivizumab) to prevent respiratory syncytial virus (RSV) infections in young children.

It's for children under 2 who are at risk for serious RSV infection in the lungs...due to premature birth or chronic lung disease.

Synagis is a monoclonal antibody. It binds to a protein on the surface of the virus to prevent it from infecting cells.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote